RAMIPRIL-2.5 CAPSULE

Страна: Канада

Език: английски

Източник: Health Canada

Активна съставка:

RAMIPRIL

Предлага се от:

SIVEM PHARMACEUTICALS ULC

АТС код:

C09AA05

INN (Международно Name):

RAMIPRIL

дозиране:

2.5MG

Лекарствена форма:

CAPSULE

Композиция:

RAMIPRIL 2.5MG

Начин на приложение:

ORAL

Броя в опаковка:

100/500

Вид предписание :

Prescription

Терапевтична област:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Каталог на резюме:

Active ingredient group (AIG) number: 0122858004; AHFS:

Статус Оторизация:

CANCELLED POST MARKET

Дата Оторизация:

2016-06-29

Данни за продукта

1
PRODUCT MONOGRAPH
PR
RAMIPRIL-2.5
PR
RAMIPRIL-5
PR
RAMIPRIL-10
RAMIPRIL CAPSULES, MANUFACTURER’S STANDARD
2.5 MG, 5.0 MG AND 10.0 MG
ANGIOTENSIN CONVERTING ENZYME INHIBITOR
SIVEM PHARMACEUTICALS ULC
4705 DOBRIN STREET
SAINT-LAURENT, QUEBEC
DATE OF PREPARATION:
H4R 2P7
JANUARY 12, 2016
CONTROL NO.: 190207
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
....................................................... 3
SUMMARY PRODUCT INFORMATION
.............................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................
3
CONTRAINDICATIONS
........................................................................................................
4
WARNINGS AND PRECAUTIONS
.......................................................................................
4
ADVERSE REACTIONS
.......................................................................................................
10
DRUG INTERACTIONS
.......................................................................................................
15
DOSAGE AND ADMINISTRATION
...................................................................................
17
OVERDOSAGE
......................................................................................................................
23
ACTION AND CLINICAL
PHARMACOLOGY..................................................................
18
STORAGE AND STABILITY
...............................................................................................
26
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................. 26
PART II: SCIENTIFIC INFORMATION
.............................................................................
23
PHARMACEUTICAL INFORMATION
...............................................................................
23
CLINICAL TRIALS
.........................................................................................................